强直性脊柱炎活跃期患者48例临床观察

Clinical Observation in 48 Active AS Patients

目的观察强直性脊柱炎活跃期患者48例来氟米特与甲氨蝶呤治疗的临床效果。方法对我院2015年4月至2017年4月收治的强直性脊柱炎活跃期患者48例的临床资料进行统计分析,依据治疗方法将这些患者分为来氟米特组(n=24)和甲氨蝶呤组(n=24)两组,对两组患者的临床疗效、不良反应发生情况进行统计分析。结果两组患者治疗的总有效率79.2%(19/24)、75.0%(18/24)之间的差异不显著(P>0.05);来氟米特组患者的不良反应发生率16.7%(4/24)显著低于甲氨蝶呤组29.2%(7/24)(P<0.05)。结论强直性脊柱炎活跃期患者来氟米特与甲氨蝶呤治疗的临床疗效相当,但前者较后者不良反应少。

Objective To observe the clinical effect of Leflunomide and Methotrexate in 48 active patients with AS(ankylosing spondylitis). Method The clinical data about 48 active AS patients treated from April 2015 to April 2017 in our hospital was collected. The subjects were divided into Leflunomide group and Methotrexate group according to the different therapies, 24 cases each group. The clinical effect and adverse event rate was analyzed. Result The total effective rate for Leflunomide group(79.2%,19/24) and Methotrexate group(75.0%,18/24) was not significantly different(P>0.05); the adverse event rate for Leflunomide group(16.7%, 4/24) was significantly lower than Methotrexate group(29.2%, 7/24)(P<0.05).Conclusion Both of Leflunomide and Methotrexate have a favorable effect in active AS patients; however, Leflunomide can greatly reduce the adverse event rate.